Neurolixis
35 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Neurolixis
Scoop.it!

Patent published on novel serotonin 5-HT1A receptor biased agonists

Patent published on novel serotonin 5-HT1A receptor biased agonists | Neurolixis | Scoop.it
New patent published by Neurolixis on novel chemical entities (NCEs) in conjunction with Jagiellonian University, Krakow. The NCEs are structural analogues of Neurolixis' lead compounds, NLX-112 and NLX-101 which are in clinical development for treatment of dyskinesia in Parkinson's disease and Rett syndrome, respectively.
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

A Castres, Neurolixis à la pointe de la recherche sur le traitement de la maladie de Parkinson

A Castres, Neurolixis à la pointe de la recherche sur le traitement de la maladie de Parkinson | Neurolixis | Scoop.it
La société américaine Neurolixis, dont la branche européenne est sise à Castres, a reçu pour ses recherches, en partie menées dans le Tarn, sur une molécule qui pourrait soulager les personnes atteintes de Parkinson, près d'un million de dollars de la fondation britannique Parkinson's UK.
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

04 December 2017 - Poster presentations at ACNP and BPS meetings

04 December 2017 - Poster presentations at ACNP and BPS meetings | Neurolixis | Scoop.it
Empty description
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

14 June 2017 - Just Published: article on NLX-112 agonist properties in vitro

A new publications characterizes the distinctive in vitro agonist properties of NLX-112, a potential drug therapy for L-DOPA-induced dyskinesia (LID) in Parkinson's disease. The study provides further support for the superior profile of NLX-112 compared to previous serotonergic agonists.

more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

24 May 2016 - Biased agonism of NLX-101 demonstrated using pharmacoMRI brain imaging

This innovative imaging study in rat provides a compelling demonstration of the selective targeting by NLX-101 of specific brain regions involved in cognition and control of mood.
Neurolixis's insight:
Share your insight
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Neurolixis Showcased in The Michael J. Fox Foundation’s Partnering Program | PRLog

Neurolixis Showcased in The Michael J. Fox Foundation’s Partnering Program | PRLog | Neurolixis | Scoop.it

Neurolixis Showcased in The Michael J. Fox Foundation’s Partnering Program. Neurolixis announced that it had been selected by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to be showcased in its Partnering Program.

more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

29 May 2015 - Neurolixis Appoints Dr. Mark H.N. Corrigan, MD, to Advisory Board

29 May 2015 - Neurolixis Appoints Dr. Mark H.N. Corrigan, MD, to Advisory Board | Neurolixis | Scoop.it

Neurolixis Inc. is delighted to announce the appointment of Mark H.N. Corrigan as a member of its Advisory Board. Dr. Corrigan has profound understanding of drug develoment and clinical trials strategy in the pharmaceutical and biotechnology environment and possesses extensive management experience in several large pharmaceutical companies.

more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

RSRT Awards $530,000 to Neurolixis for Clinical Development of NLX-101

RSRT Awards $530,000 to Neurolixis for Clinical Development of NLX-101 | Neurolixis | Scoop.it

RSRT recently awarded $530,000 to Neurolixis, a small biotech firm in southern California that is developing the drug, NLX-101, to treat breathing abnormalities in people affected by Rett Syndrome.

more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

What Is Parkinson's Disease? Symptoms, Diagnosis

What Is Parkinson's Disease? Symptoms, Diagnosis | Neurolixis | Scoop.it
Parkinson's Disease can be scary and overwhelming, but it is also not well understood. Know what is parkinson’s disease, it’s symptoms and diagnosis.
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Preferential Targeting of Subpopulations of 5-HT1A Receptors: Microdialysis Study on potential antidyskinetic drugs

Preferential Targeting of Subpopulations of 5-HT1A Receptors: Microdialysis Study on potential antidyskinetic drugs | Neurolixis | Scoop.it
more...
No comment yet.
Rescooped by Neurolixis from Rett syndrome and breathing difficulties
Scoop.it!

European Commission approves Orphan Medicinal Product designation for NLX-101

European Commission approves Orphan Medicinal Product designation for NLX-101 | Neurolixis | Scoop.it

Neurolixis receives Orphan Medicinal Product designation for treatment of Rett syndrome
http://t.co/RpShnC7iR6)...


Via Adrian Newman-Tancredi
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Bristol University Launches New Rett Syndrome Research on Promising Drug

Bristol University Launches New Rett Syndrome Research on Promising Drug | Neurolixis | Scoop.it
Scientists at the University of Bristol have received $300,000 (£180,000) thanks to a partnership between the International Rett Syndrome Foundation and Cure Rett to test a powerful new drug, called NLX-101, which may ...
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Face to Face with Rett Syndrome

Our 11 year old daughter Chelsea is afflicted with Rett Syndrome. This video is a slide show of her life so far, dovetailing into Monica's new organization, ...
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Les espoirs de Neurolixis dans la recherche sur la maladie de Parkinson - 22/02/2018

Les espoirs de Neurolixis dans la recherche sur la maladie de Parkinson - 22/02/2018 | Neurolixis | Scoop.it

La société Neurolixis pilotée à Castres par Adrian Newman-Tancredi, ancien chercheur chez Pierre-Fabre, vient de lever 1 million de dollars afin de poursuivre la recherche sur une molécule très prometteuse dans le traitement du Parkinson.

more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Parkinson's UK partners with Neurolixis

Parkinson's UK partners with Neurolixis | Neurolixis | Scoop.it
Parkinson's UK is partnering with US company Neurolixis to accelerate the development of a promising new drug that could prevent dyskinesia, one of the most debilitating side effects of Parkinson's medication.
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

This French Biotech is Taking On CNS Diseases of the Young and the Elderly

This French Biotech is Taking On CNS Diseases of the Young and the Elderly | Neurolixis | Scoop.it
The European Biotech News Website
Neurolixis's insight:
Neurolixis showcased online by "LaBiotech"
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

20 December 2016 - Neurolixis CSO presents at Encéphale Congress in Paris

20 December 2016 - Neurolixis CSO presents at Encéphale Congress in Paris | Neurolixis | Scoop.it
Dr. Newman-Tancredi will gave a lecture as part of the plenary session entitled "Psychopharmacology in the Third Millennium" on Wednesday 18 January 2017. The focus is on prospects for improved treatment of depressive disorders using highly selective 'biased agonists' targeting cortical serotonin 5-HT1A receptors.
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

16 November 2015 - Neurolixis Appoints Dr. Steven A. Johnson, PhD, as VP for Drug Development

neurolixis joomla3
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

04 June 2015 - Neurolixis SAS awarded French 'Young Innovative Company' status

04 June 2015 - Neurolixis SAS awarded French 'Young Innovative Company' status | Neurolixis | Scoop.it
neurolixis joomla3
Neurolixis's insight:

The prestigious 'Young Innovative Company' ('Jeune Entreprise Innovante') status awards Neurolixis reductions in social charges and access to tax credits.

more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. | Neurolixis | Scoop.it

Experimental Neurology. 2015 May 30. pii: S0014-4886(15)30008-X. doi: 10.1016/j.expneurol.2015.05.021. [Epub ahead of print]

Neurolixis's insight:

This study describes the activity of NLX-112 in a range of roddent models of Parkinson's Disease and mood deficits.

more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Psychiatric Symptoms Emerge Early in Parkinson’s Disease—And Often Go Untreated

Psychiatric Symptoms Emerge Early in Parkinson’s Disease—And Often Go Untreated | Neurolixis | Scoop.it
RT @NeurologyNow: Psychiatric symptoms emerge early in Parkinson's disease, and often go untreated http://t.co/DS7Voc77s2 #parkinsons
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations

In the recent years the serotonin system has emerged as a key player in the induction of L-DOPA-induced dyskinesia in animal models of Parkinson’s disease. In fact, serotonin neurons possess the en...
more...
No comment yet.
Rescooped by Neurolixis from Parkinson's disease and serotonin
Scoop.it!

NLX-112: a novel drug for treatment of L-DOPA-induced dyskinesia

NLX-112: a novel drug for treatment of L-DOPA-induced dyskinesia | Neurolixis | Scoop.it

 

NLX-112 is a highly selective serotonergic drug that has the potential to greatly diminish L-DOPA-induced dyskinesia in Parkinson's disease.


Via Adrian Newman-Tancredi
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

Global Parkinson’s Disease Therapeutics Market Value to Reach $5.3 Billion by 2022 as Current Pipeline Addresses Advanced Patients

Global Parkinson’s Disease Therapeutics Market Value to Reach $5.3 Billion by 2022 as Current Pipeline Addresses Advanced Patients | Neurolixis | Scoop.it
Reportstack has announced a new report on Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022.  According to this report, the US will have the largest PD therapeutics market share
more...
No comment yet.
Scooped by Neurolixis
Scoop.it!

5-HT1A Receptor Biased Agonism - lecture by Neurolixis CSO

Lecture delivered at the 25th Congress of the European College of Neuropsychopharmacology, Vienna (Austria), Monday 15 October 2012.

more...
No comment yet.